Mode
Text Size
Log in / Sign up
N/A Completed N=288

Study Evaluating Refacto For Pharmacovigilance

Source: ClinicalTrials.gov NCT00195442 ↗
Enrolled (actual)
288
Serious AEs
49.0%
Results posted
Feb 2011
Primary outcomePrimary: Mean Number of Bleeding Episodes Per Patient Year — 13.41 episodes per year

Summary

The purpose of this study is to investigate the effectiveness and safety of treatment with ReFacto under conditions of routine therapy. Furthermore a continuous benefit/risk assessment will be done.

Outcome Measures

OutcomeResultp-value
PRIMARY
Mean Number of Bleeding Episodes Per Patient Year
13.41 —
PRIMARY
Mean Number of Bleeding-related Exposure Days Per Patient Year
20.58 —
PRIMARY
Mean Number of Exposure Days Per Patient Year
126.76 —
SECONDARY
Number of Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs)
668; 291 —
SECONDARY
Number of Participants With de Novo Inhibitor Formation
7 —
SECONDARY
Mean Annual ReFacto Consumption Per Patient Year
204509 —
SECONDARY
Number of Participants for Physicians' Assessment of Satisfaction With Treatment Success
92; 73; 3; 1 —
SECONDARY
Number of Participants for Physicians' Assessment of Efficacy
111; 111; 38; 9 —
SECONDARY
Number of Participants for Patients' Assessment of Efficacy
103; 116; 35; 11; 4 —
SECONDARY
Number of Participants for Physicians' Assessment of Tolerance
130; 137; 2 —
SECONDARY
Number of Participants for Patients' Assessment of Tolerance
131; 132; 1; 1; 4 —
SECONDARY
Number of Participants for Physicians' Assessment of Handling of ReFacto
109; 154; 6 —
SECONDARY
Number of Participants for Patients' Assessment of Handling of ReFacto
99; 154; 11; 1; 4 —
SECONDARY
Number of Participants for Days of Sick Leave Per Month
87; 32; 4; 8; 0; 36 —

Eligibility Criteria

Inclusion Criteria

  • Proven diagnosis of Hemophilia A

Exclusion Criteria

  • Contraindications according to Summary of Product Characteristics
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00195442). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search